LivaNova (NASDAQ:LIVN) Issues Quarterly Earnings Results

LivaNova (NASDAQ:LIVN) released its quarterly earnings results on Wednesday. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13, Briefing.com reports. The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 earnings per share. LivaNova updated its FY 2026 guidance to 4.200-4.300 EPS.

Here are the key takeaways from LivaNova’s conference call:

• Company raised full-year 2026 guidance to 7%–8% revenue growth and increased adjusted EPS to $4.20–$4.30, reflecting stronger-than-expected Q1 performance and continued top-line momentum.
• Cardiopulmonary strength: HLM revenue grew in the high teens driven by Essenz upgrade adoption, consumables gained share, and a new manufacturing line (2H26) plus supplier improvements should enable low double-digit output growth and upside to consumables supply.
• Epilepsy tailwinds: U.S. Medicare reimbursement for VNS increased ~48% for new implants (effective Jan 1, 2026) and favorable core VNS study data are improving pricing, reducing discounts, and expected to expand procedure penetration over time.
• Major regulatory and clinical milestones in OSA — FDA PMA approval of the aura6000 and 12‑month OSPREY RCT results (plus PolySync conversion data) materially de‑risk commercialization, but near‑term reimbursement ambiguity and market dynamics leave timing/scale of uptake uncertain.
• Near‑term cash and FCF pressure: cash declined to $540M, adjusted free cash flow was only $4M in Q1 due to higher capital spend and working capital, and full‑year capex is planned at $120M, weighing on short‑term cash conversion.

LivaNova Trading Up 7.0%

NASDAQ:LIVN opened at $70.93 on Friday. The firm has a market cap of $3.90 billion, a P/E ratio of 36.37 and a beta of 0.82. The company has a current ratio of 1.33, a quick ratio of 1.16 and a debt-to-equity ratio of 0.24. The stock’s 50 day simple moving average is $64.01 and its 200-day simple moving average is $62.15. LivaNova has a 12-month low of $41.01 and a 12-month high of $71.92.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new stake in shares of LivaNova in the 4th quarter valued at approximately $302,000. Pacer Advisors Inc. raised its position in LivaNova by 131.7% in the fourth quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after acquiring an additional 9,471 shares in the last quarter. Invesco Ltd. raised its position in LivaNova by 4.5% in the fourth quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after acquiring an additional 47,323 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in LivaNova in the fourth quarter worth $306,000. Finally, State of Tennessee Department of Treasury raised its position in LivaNova by 44.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 30,304 shares of the company’s stock worth $1,991,000 after acquiring an additional 9,396 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on LIVN. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price target on shares of LivaNova in a research report on Friday, January 9th. Barclays lifted their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday. Stifel Nicolaus set a $80.00 target price on LivaNova in a report on Wednesday, February 25th. Needham & Company LLC boosted their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Piper Sandler reissued an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus target price of $77.22.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.